scholarly journals Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients

2018 ◽  
Vol 76 (7) ◽  
pp. 452-458 ◽  
Author(s):  
Sahar Mohamed El-Haggar ◽  
Tarek Mohamed Mostafa ◽  
Horeya Mohamed Sad Allah ◽  
Ghada Hassan Akef
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Biochemical Markers ◽  
Serum Alkaline Phosphatase ◽  
Mineral Metabolism ◽  
Significant Negative Correlation ◽  
Bone Resorption Marker ◽  
Monotherapy Group ◽  
Mineral Density ◽  
Bone Formation Markers

ABSTRACT The purpose of this study was to determine the effect of lamotrigine (LTG) and levetiracetam (LEV) as mono- and polytherapy on biochemical markers of bone turnover and bone mineral density in Egyptian adult patients with epilepsy. Methods Forty-eight patients were divided into four groups: two received monotherapy of either LTG or LEV, and the other two groups received polytherapy comprising (valproate [VPA] + LTG or VPA + LEV). Thirty matched healthy participants were included in the study. Participants completed a nutritional and physical activity questionnaire. Biochemical markers of bone and mineral metabolism and bone mineral density of the lumbar spine were measured at baseline and at six months. Results In the LEV monotherapy group, the bone formation markers showed a significant decrease in serum alkaline phosphatase and serum osteocalcin levels while the bone resorption marker showed a significant increase in urinary deoxypyridinoline levels. After six months of treatment, bone mineral density showed a significant decrease in all treated groups, while among monotherapy groups, this significant decrease was more prevalent in the LEV monotherapy group compared with the LTG monotherapy group. Furthermore, there was significant negative correlation between urinary deoxypyridinoline levels and bone mineral density in the LEV monotherapy group. Conclusion Using new generation antiepileptics, LEV monotherapies and polytherapy showed harmful effects on bone but LTG did not.

scholarly journals Smoking cessation increases levels of osteocalcin and uncarboxylated osteocalcin in human sera

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yasuhiro Kiyota ◽  
Hiroyasu Muramatsu ◽  
Yuiko Sato ◽  
Tami Kobayashi ◽  
Kana Miyamoto ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Smoking Cessation ◽  
Bone Mineral ◽  
Serum Levels ◽  
Tartrate Resistant Acid Phosphatase ◽  
Bone Resorption Marker ◽  
Bone Homeostasis ◽  
Mineral Density ◽  
Serum Cotinine ◽  
Bone Formation Markers

Abstract Smoking is thought to be a risk factor for osteoporosis development; however, the consequences of stopping smoking for bone homeostasis remain unknown. Here we conducted two separate human studies and show that bone mineral density was significantly lower in smokers than in non-smokers. The first was an observational study of pre- and post-menopausal healthy female smokers and non-smokers; the second included 139 current smokers determined to stop smoking. In the second study, levels of bone formation markers such as osteocalcin and uncarboxylated osteocalcin significantly increased after successful smoking cessation, as verified by significantly reduced levels of serum cotinine, a nicotine metabolite. Moreover, nicotine administration to mice reduced bone mineral density and significantly increased the number of osteoclasts in bone. Reduced bone mass phenotypes seen in nicotine-treated mice were significantly increased following nicotine withdrawal, an outcome accompanied by significantly reduced serum levels of tartrate-resistant acid phosphatase, a bone resorption marker. Taken together, our findings suggest that bone homeostasis is perturbed but can be rescued by smoking cessation.

scholarly journals Association of serum chemerin with calcium, alkaline phosphatase and bone mineral density in postmenopausal females

2021 ◽  
Vol 37 (2) ◽  
Author(s):  
Saba Tariq ◽  
Sundus Tariq ◽  
Muhammad Shahzad
Keyword(s):  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Bone Mineral ◽  
Serum Alkaline Phosphatase ◽  
Linear Regression Analysis ◽  
Significant Negative Correlation ◽  
Mineral Density ◽  
Creative Commons ◽  
Significant Difference ◽  
Section Analysis

Objectives: To investigate the association of serum chemerin with calcium, alkaline phosphatase and bone mineral density in postmenopausal non-osteoporotic and osteoporotic females. Methods: This cross-section analysis was carried out at the orthopedic department of Madina Teaching Hospital, Faisalabad, Pakistan, in the year 2017-2019. Postmenopausal females were divided into two groups according to their bone mineral density (BMD). All osteoporotic females had a T-score of -2.5 or less. Data were analyzed on SPSS-24. Results: A total of 140 women were included in our study (80 osteoporotic and 60 non-osteoporotic). Non significant difference in age and BMI was observed between osteoporotic and non-osteoporotic subjects (p=0.152) and (p=0.291) respectively. There was a significant difference found in total BMD, serum chemerin levels between osteoporotic and non-osteoporotic subjects p<0.001 in both parameters. No significant correlation of serum chemerin was found with serum calcium, serum alkaline phosphatase and BMD in postmenopausal osteoporotic females (p=0.907), (p=0.318) (p=0.664) respectively. A significant negative correlation was found between serum alkaline phosphatase levels and total BMD in postmenopausal osteoporotic females (p=- 0.039). Linear regression analysis of serum alkaline phosphatase levels with total BMD showed no association between BMD and serum alkaline phosphatase levels (p=0.869). Conclusion: There is no association of serum chemerin with calcium, ALP and bone mineral density in non-osteoporotic and osteoporotic postmenopausal females. doi: https://doi.org/10.12669/pjms.37.2.3907 How to cite this:Tariq S, Tariq S, Shahzad M. Association of serum chemerin with calcium, alkaline phosphatase and bone mineral density in postmenopausal females. Pak J Med Sci. 2021;37(2):---------. doi: https://doi.org/10.12669/pjms.37.2.3907 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract #510 Mineral Metabolism and Bone Mineral Density in Patients with Neuroendocrine Tumors

2018 ◽  
Vol 24 ◽  
pp. 110-111
Author(s):  
Franco Grimaldi ◽  
Elda Kara ◽  
Fabio Vanin ◽  
Maria Carpentieri ◽  
Claudia Cipri ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Neuroendocrine Tumors ◽  
Bone Mineral ◽  
Mineral Metabolism ◽  
Mineral Density

scholarly journals Serum leptin concentration, bone mineral density and bone biochemical markers in a sample of Egyptian women: A possible relationship

2011 ◽  
Vol 33 (4) ◽  
pp. 171-177 ◽  
Author(s):  
Soha Eldessouki Ibrahim ◽  
Heba F. ElShishtawy ◽  
Amir Helmy ◽  
Zeinab A. Galal ◽  
Maha Hussein Abdel Salam
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Biochemical Markers ◽  
Mineral Density ◽  
Serum Leptin ◽  
Bone Biochemical Markers ◽  
Egyptian Women

scholarly journals Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
A. Sánchez ◽  
L. R. Brun ◽  
H. Salerni ◽  
P. R. Costanzo ◽  
D. González ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Similar Response ◽  
Mineral Density ◽  
Turnover Markers

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

Effects of dietary protein deficiency on mineral metabolism and bone mineral density

1992 ◽  
Vol 56 (2) ◽  
pp. 314-319 ◽  
Author(s):  
E Orwoll ◽  
M Ware ◽  
L Stribrska ◽  
D Bikle ◽  
T Sanchez ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Dietary Protein ◽  
Mineral Metabolism ◽  
Protein Deficiency ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document